浙江新和成股份有限公司 2019 年年度报告全文 浙江新和成股份有限公司 2019 年年度报告 2020 年 04 月 浙江新和成股份有限公司 2019 年年度报告全文 1 第一节重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连 带的法律责任。 公司负责人胡柏藩、主管会计工作负责人石观群及会计机构负责人(会计主 管人员)王晓碧声明：保证年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本年度报告涉及未来计划等前瞻性陈述，不构成公司对投资者的实质承诺， 能否实现取决于市场状况变化、经营团队的努力程度等多种因素，存在很大的 不确定性，敬请广大投资者注意投资风险。 公司经本次董事会审议通过的利润分配预案为：以 2,148,662,300 为基数， 向全体股东每 10 股派发现金红利 5 元（含税），送红股 0 股（含税），不以公积 金转增股本。 浙江新和成股份有限公司 2019 年年度报告全文 目录 | --- | --- | |----------------------- ...

浙江新和成股份有限公司 2018 年年度报告 2019 年 04 月 浙江新和成股份有限公司 2018 年年度报告全文 1 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连 带的法律责任。 公司负责人胡柏藩、主管会计工作负责人石观群及会计机构负责人(会计主 管人员)石方彬声明：保证年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本年度报告涉及未来计划等前瞻性陈述，不构成公司对投资者的实质承诺， 能否实现取决于市场状况变化、经营团队的努力程度等多种因素，存在很大的 不确定性，敬请广大投资者注意投资风险。 公司经本次董事会审议通过的利润分配预案为：以 2,148,662,300 为基数， 向全体股东每 10 股派发现金红利 7.00 元（含税），送红股 0 股（含税），不以公 积金转增股本。 浙江新和成股份有限公司 2018 年年度报告全文 录 目 | --- | |-------------------------------------------| | | ...

Financial Performance - Net profit attributable to shareholders rose by 51.96% to CNY 478,844,727.91 for the reporting period[8] - Operating revenue for the period reached CNY 2,068,257,247.53, reflecting a 39.36% increase year-on-year[8] - Basic earnings per share increased by 29.41% to CNY 0.22[8] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 417,602,993.38, up 37.45%[8] - The company reported a significant increase in net profit for the year-to-date, up 181.60% to CNY 2,537,389,099.04[8] - The net profit attributable to shareholders for 2018 is expected to range from CNY 289,750.28 million to CNY 340,882.68 million, representing a year-on-year increase of 70% to 100%[25] - The net profit for 2017 was CNY 170,441.34 million, indicating significant growth in profitability for 2018[25] - The increase in net profit is primarily due to higher average sales prices of the company's leading products compared to the same period last year[25] Assets and Liabilities - Total assets increased by 12.58% to CNY 20,469,666,311.43 compared to the end of the previous year[8] - The company's cash and cash equivalents decreased by 64.39% compared to the beginning of the year, primarily due to the purchase of financial products during the reporting period[16] - The company's short-term borrowings increased by 36.03% compared to the beginning of the year, indicating a rise in short-term financing[16] - The company's prepayments increased by 58.13% compared to the beginning of the year, mainly due to higher advance payments for raw materials[16] - The company's intangible assets increased by 99.28% compared to the beginning of the year, primarily due to the acquisition of new land[16] - The company's deferred income increased by 231.74% compared to the beginning of the year, mainly due to an increase in subsidies related to received assets[16] Cash Flow - The net cash flow from operating activities surged by 84.73% to CNY 690,756,388.37[8] - The company's net cash flow from operating activities increased by 209.26% year-on-year, primarily due to increased sales revenue[18] Shareholder Information - The total number of shareholders at the end of the reporting period was 85,668[12] - The largest shareholder, Xinhacheng Holdings Group, holds 48.55% of the shares[12] Investment and Expenses - Investment income for the first three quarters increased by 196.86% year-on-year, influenced by higher returns from financial products[18] - Research and development expenses for the first three quarters increased by 45.12% year-on-year, reflecting the company's increased investment in R&D[17] - The company experienced a 77.42% year-on-year decrease in financial expenses, attributed to currency exchange rate fluctuations during the reporting period[17] Financial Management - The company has no non-operating fund occupation by controlling shareholders or related parties during the reporting period[27] - The company has engaged in entrusted financial management, with a total amount of CNY 1,252,000 million, including CNY 1,240,000 million from raised funds[29] - The remaining balance of entrusted financial management is CNY 400,000 million, with no overdue amounts[29] - There are no significant or high-risk entrusted financial management situations reported during the period[30] - The company has committed to fulfilling its obligations to minority shareholders without any unfulfilled commitments[24] - The company is committed to maintaining compliance with its financial management practices and has no violations reported[26] Other Information - The weighted average return on equity decreased by 0.76 percentage points to 3.11%[8] - The company has not engaged in any research, communication, or interview activities during the reporting period[30]

Financial Performance - The company's operating revenue for the first half of 2018 was ¥4,651,169,915.08, representing a 78.34% increase compared to ¥2,608,022,394.08 in the same period last year[19]. - The net profit attributable to shareholders of the listed company reached ¥2,058,544,371.13, a significant increase of 251.32% from ¥585,944,554.24 in the previous year[19]. - The net profit after deducting non-recurring gains and losses was ¥2,005,950,369.02, up 260.17% from ¥556,937,962.33 year-on-year[19]. - The net cash flow from operating activities was ¥1,364,262,252.46, an increase of 220.76% compared to ¥425,324,715.20 in the same period last year[19]. - Basic and diluted earnings per share were both ¥0.96, reflecting a 200.00% increase from ¥0.32 in the previous year[19]. - The weighted average return on equity rose to 13.87%, an increase of 6.86 percentage points from 7.01% in the previous year[19]. - Total assets at the end of the reporting period were ¥19,705,075,722.38, an increase of 8.37% from ¥18,182,814,769.32 at the end of the previous year[19]. - Net assets attributable to shareholders of the listed company increased by 8.45% to ¥15,135,919,026.43 from ¥13,956,928,415.97 at the end of the previous year[19]. Revenue and Profit Growth - The company achieved total revenue of CNY 465,116.99 million, an increase of 78.34% compared to the same period last year[35]. - The total profit reached CNY 243,915.54 million, reflecting a significant increase of 254.68% year-on-year[35]. - Net profit attributable to shareholders was CNY 205,854.44 million, up by 251.32% compared to the previous year[35]. - The vitamin A price significantly increased, contributing to the rise in total revenue and net profit[26]. - The company’s vitamin product market share is high, with a prominent position both domestically and internationally[26]. - The company’s R&D efforts led to an 86.98% growth in the nutrition business and a 56.73% increase in the fragrance business[35]. Investment and Assets - The company’s intangible assets grew by 87.71% due to the acquisition of new land[28]. - The company’s construction in progress increased by 130.34%, primarily due to new project investments[28]. - The company plans to enhance its new materials business, focusing on expanding overseas markets and optimizing processes[27]. - The company’s cash and cash equivalents decreased by 66.67% due to investments in financial products[28]. - The investment income increased by 97.53% to ¥57,470,769.89 from ¥29,094,517.55, mainly driven by higher returns from financial products[39]. - The total investment amount for the reporting period reached ¥1,070,311,976.71, representing a significant increase of 275.85% compared to the previous year[51]. Cash Flow and Financing - The net cash flow from investing activities was negative at ¥-5,460,569,118.65, reflecting increased investments in financial products and new projects[39]. - The company raised a total of ¥4,900,000,000.00 through a private placement of 175,000,000 shares at ¥28.00 per share, with a net amount of ¥4,867,075,471.70 after deducting issuance costs[58]. - The cumulative amount of raised funds utilized during the reporting period was ¥88,134,100, with a remaining balance of ¥483,407,470[58]. - The company has committed to an investment project for an annual production of 250,000 tons of methionine, with a total investment of ¥486,707.5 million[61]. Regulatory and Compliance - The company is facing increased regulatory scrutiny regarding environmental protection, necessitating higher standards for safety and energy management[75]. - The company reported a significant legal case involving a commercial secret infringement, with a compensation amount of 35 million yuan and additional reasonable costs of 220,000 yuan awarded to the plaintiff[84]. - The company has maintained a high level of compliance with commitments made regarding competition and related transactions[80]. - The half-year financial report has not been audited, indicating a potential area of concern for investors[82]. Environmental Responsibility - The company has committed to sustainable development through comprehensive green environmental operations from R&D to production[76]. - The company has implemented a comprehensive wastewater treatment system to ensure effective pollution control[104]. - The company has adopted advanced gas treatment technologies, including activated carbon recovery systems, to minimize emissions[104]. - The company has established a standard hazardous waste storage facility and incineration system for solid waste management[104]. - The company emphasizes green development and has integrated clean production concepts into its operations[103]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 76,960[118]. - The largest shareholder, New Hecheng Holdings Group Co., Ltd., holds 48.55% of the shares, totaling 1,043,253,037 common shares[118]. - The company did not experience any changes in its controlling shareholder during the reporting period[121]. - The company did not issue any preferred shares during the reporting period[124]. Financial Position - The company's total liabilities increased to CNY 4,521,725,125.29 from CNY 4,186,694,247.70, representing a rise of about 8.00%[136]. - The total equity attributable to shareholders rose to CNY 15,135,919,026.43, up from CNY 13,956,928,415.97, indicating an increase of approximately 8.43%[137]. - The company's retained earnings increased from CNY 6,637,883,274.34 to CNY 7,811,684,345.47, reflecting a growth of about 17.66%[137]. Accounting and Financial Reporting - The company adheres to the enterprise accounting standards, ensuring that its financial statements accurately reflect its financial position and operating results[174]. - The company classifies financial assets into four categories at initial recognition, including financial assets measured at fair value with changes recognized in profit or loss[184]. - Financial liabilities are classified into two categories at initial recognition, including those measured at fair value with changes recognized in profit or loss[184].

Financial Performance Forecast - The company expects a net profit attributable to shareholders for the first half of 2018 to be between 2,021.51 million yuan and 2,197.29 million yuan, a decrease of 245% to 275% compared to the same period last year[3]. - The previous forecast estimated a net profit of 2,226.59 million yuan to 2,519.56 million yuan for the same period[3]. - The net profit for the same period last year was 585.94 million yuan[3]. Reasons for Decline - The decline in net profit is attributed to a decrease in the sales price of vitamin E and a reduction in product gross margin[5]. Audit and Finalization - The performance forecast revision has not been audited by registered accountants[4]. - The financial data provided is preliminary and will be finalized in the company's 2018 semi-annual report[6]. Apology to Investors - The company has expressed sincere apologies for any inconvenience caused to investors due to the performance forecast revision[7].